About DRG Epidemiology
DRG’s Epidemiology provides bottom-up, patient-level forecasts, detailing disease trends from 10- to 20-year outlook periods to help you validate investments and identify growth opportunities in your markets of interest.
All of our epidemiological data, methods and insight are distributed via DRG’s Insights Platform, allowing the user to easily navigate between world regions and patient populations, as well as download epidemiological forecast data into an MS Excel format for offline use.
All epidemiological forecasts may be supplemented with custom deliverables, such as:
- Chart reviews or more granular stratification using DRG’s in-house real world datasets or physician survey data
- Customized and interactive patient flow models or additional subpopulations or metrics
- Expanded geographical coverage or extended forecast periods beyond those available
Our robust patient population sizing data includes therapeutic coverage of 140+ indications and 3400+ patient subpopulations, including extensive oncology subpopulation data by stage, line of therapy, and biomarker, as well as continually expanding niche and rare disease coverage.
The geographic breadth of data includes mature market (G7) reporting for all 140+ indications, as well as 90% global population coverage for the high-profile diseases, and expanded penetration for emerging and rest-of-world markets in select indications.
For over 20 years, our data and methodology have been developed and refined by DRG’s Epidemiology team of industry-leading subject matter experts, driven by rigorous methodology to uncover the impact of exposure, risk, and treatment, in addition to historical trends and age and gender cohorts.
All of our epidemiological forecasts are accompanied by a transparent description of our methods and data sources, the details of our systematic review underlying each forecast and associated summary evidence tables, and access to the authoring epidemiologist.
- Middle East & Africa Data
- Key Findings
- Total Prevalence of Dementia per 1,000 People Aged 65+ in 2016 and 2026
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Dementia over the Next Ten Years
- Total Prevalent Cases of Dementia by Severity
- Epidemiology Data
- Total Prevalence
- Total Prevalent Cases by Severity
- Reference Materials
- Literature Review
- Risk/Protective Factors
Author(s): Nishant Kumar, MPH
Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects. His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.